About

Team

Dr. Wolfgang Klein, CEO
Dr. Thorsten Meyer,
Regulatory Affairs
Roland Mirow,
Business Development
Prof. Ulrich Schraermeyer,
Science
Dr. Michael Burnet, Development
Dr. Sylvie Julien-Schraermeyer, Science

History

2011: Foundation of Katairo with the main purpose of developing its lead compound Remofuscin for the treatment of Stargardt disease

2013: Orphan drug designation for Remofuscin for the treatment of Stargardt disease in the EU.

2017: Licensing of extensive data and relevant IP rights from the original developer of Katairo's lead compound

2017: EU funding for a Phase 2 clinical proof-of-concept trial together with a European consortium.

2017: Orphan drug designation for Remofuscin for the treatment of Stargardt disease in the USA.